Product
IP FT516
1 clinical trial
3 indications
Indication
Ovarian CancerIndication
Fallopian Tube AdenocarcinomaIndication
Primary Peritoneal Cavity CancerClinical trial
Intraperitoneal FATE FT516 and Interleukin-2 (IL-2) With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerStatus: Completed, Estimated PCD: 2022-01-01